These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2672964)

  • 1. Membrane modifiers in sickle cell disease.
    Benjamin LJ
    Ann N Y Acad Sci; 1989; 565():247-61. PubMed ID: 2672964
    [No Abstract]   [Full Text] [Related]  

  • 2. Extracorporeal treatment of erythrocytes in sickle cell anemia: hemoglobin carbamylation.
    Diederich D; Curran M; Odenbaugh A; Diederich A; Core E
    Tex Rep Biol Med; 1980-1981; 40():313-22. PubMed ID: 7323976
    [No Abstract]   [Full Text] [Related]  

  • 3. Understanding antisickling agents and the sickling process.
    Godwin M; Baysinger M
    Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
    [No Abstract]   [Full Text] [Related]  

  • 4. Physiologic and rheologic effects of the antisickling agent ethacrynic acid and its N-butylated derivative on normal and sickle erythrocytes.
    Orringer EP; Blythe DS; Whitney JA; Brockenbrough S; Abraham DJ
    Am J Hematol; 1992 Jan; 39(1):39-44. PubMed ID: 1536139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular basis of antisickling agents.
    Franklin IM; Huehns ER
    Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of cetiedil on erythrocyte sickling: new type of antisickling agent that may affect erythrocyte membranes.
    Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Singer M; Russell MO; Schwartz E
    Proc Natl Acad Sci U S A; 1980 May; 77(5):2955-9. PubMed ID: 6930678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisickling effects of membrane-interacting compounds.
    Ohnishi ST
    Blood Cells; 1982; 8(2):337-43. PubMed ID: 6130805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
    Abdulmalik O; Pagare PP; Huang B; Xu GG; Ghatge MS; Xu X; Chen Q; Anabaraonye N; Musayev FN; Omar AM; Venitz J; Zhang Y; Safo MK
    Sci Rep; 2020 Nov; 10(1):20277. PubMed ID: 33219275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisickling effect of chrysin is associated with modulation of oxygenated and deoxygenated haemoglobin via alteration of functional chemistry and metabolic pathways of human sickle erythrocytes.
    Nwankwo HC; Idowu AA; Muhammad A; Waziri AD; Abubakar YS; Bashir M; Erukainure OL
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S108-S124. PubMed ID: 34151613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacology for Pediatricians. II. Antisickling agents, with special reference to new vasoerythroactive drugs.
    Cho YW; Aviado DM
    J Clin Pharmacol; 1982 Jan; 22(1):1-13. PubMed ID: 7037870
    [No Abstract]   [Full Text] [Related]  

  • 11. New antisickling agents.
    Labie D
    Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of piracetam on sickle erythrocytes and sickle hemoglobin.
    Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Devlin MT; Schwartz E
    Biochim Biophys Acta; 1981 May; 668(3):397-405. PubMed ID: 7236716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent chemical modifiers of sickle cell hemoglobin.
    Ueno H; Bai Y; Manning JM
    Ann N Y Acad Sci; 1989; 565():239-46. PubMed ID: 2774426
    [No Abstract]   [Full Text] [Related]  

  • 14. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro effects of anthocyanin extracts from Justicia secunda Vahl on the solubility of haemoglobin S and membrane stability of sickle erythrocytes.
    Mpiana PT; Ngbolua KN; Bokota MT; Kasonga TK; Atibu EK; Tshibangu DS; Mudogo V
    Blood Transfus; 2010 Oct; 8(4):248-54. PubMed ID: 20967165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antisickling agent 3,4-dihydro-2,2-dimethyl-2h-1 benzopyran-6-butyric acid.
    Ekong DE; Okogun JI; Enyenihi VU; Balogh-Nair V; Nakanishi K; Natta C
    Nature; 1975 Dec; 258(5537):743-6. PubMed ID: 1207760
    [No Abstract]   [Full Text] [Related]  

  • 17. Established and experimental treatments for sickle cell disease.
    De Franceschi L; Corrocher R
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of glyceraldehyde on the structural and functional properties of sickle erythrocytes.
    Nigen AM; Manning JM
    J Clin Invest; 1978 Jan; 61(1):11-9. PubMed ID: 618907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sickle cell (II): many agents near trials.
    Maugh TH
    Science; 1981 Jan; 211(4481):468-70. PubMed ID: 6161416
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
    Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE
    Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.